Currently, an antibody against the COOH-terminal domain of GPR78 (anti-CTD antibody) can downregulate pro-proliferative signaling and upregulate p53 in prostate cancer cells and melanoma cells,196 and GPR78 protein expression was significantly regulated by miR-936 in laryngeal squamous cell carcinoma (LSCC) cells,197 suggesting two possible approaches to target GPR78, but no relevant clinical trials have yet been conducted. The gene discussed is GPR78; the disease is prostate carcinoma.